- Home
- ANGH vs BLRX Comparison
ANGH vs BLRX Comparison
Compare ANGH & BLRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ANGH | BLRX |
|---|---|---|
| Founded | 2012 | 2003 |
| Country | United Arab Emirates | Israel |
| Employees | N/A | N/A |
| Industry | Telecommunications Equipment | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 16.8M | 17.1M |
| IPO Year | N/A | 2011 |
Fundamental Metrics
Financial Performance| Metric | ANGH | BLRX |
|---|---|---|
| Price | $2.65 | $3.17 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $19.00 |
| AVG Volume (30 Days) | 8.9K | ★ 28.9K |
| Earning Date | 04-30-2026 | 11-24-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $78,093,405.00 | $12,735,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 88.72 | N/A |
| 52 Week Low | $2.46 | $2.30 |
| 52 Week High | $8.88 | $14.70 |
Technical Indicators
Market Signals| Indicator | ANGH | BLRX |
|---|---|---|
| Relative Strength Index (RSI) | 28.69 | 46.97 |
| Support Level | $2.50 | $3.16 |
| Resistance Level | $3.00 | $3.43 |
| Average True Range (ATR) | 0.13 | 0.22 |
| MACD | -0.05 | 0.01 |
| Stochastic Oscillator | 11.11 | 26.03 |
Price Performance
Historical ComparisonAbout ANGH Anghami Inc.
Anghami Inc is a digital music entertainment technology platform in the Middle East and North Africa, with a catalog of songs. The company features licensed content from Arabic labels, independent artists, and distributors. It also features music from International labels such as Universal, Sony, and Warner Music. It generates the majority of its revenue from subscriptions.
About BLRX BioLineRx Ltd.
BioLine Rx Ltd is a commercial-stage biopharmaceutical company focused on oncology. The company's current development and commercialization pipeline consists of two clinical-stage therapeutic candidates motixafortide (BL-8040), a novel peptide for the treatment of stem-cell mobilization and solid tumors, and AGI-134, an immuno-oncology agent in development for solid tumors. In addition, the company has a legacy therapeutic product called BL-5010 for the treatment of skin lesions. The company has generated revenues from milestone payments under previously existing out-licensing agreements.